Health-tech startups need patience; deep-tech’s in favour now: Endiya Partners' Ramesh Byrapaneni
Some startups fail due to excessive focus on achieving rapid growth at any cost and attaining unicorn status, says Ramesh Byrapaneni, managing director, Endiya Partners. Speaking to ET Prime, he discusses why investors are getting attracted to deep-tech firms, and his take on the ventures from his portfolio that are likely to become big in near future.
The recent launch of the draft National Deeptech Policy is well-timed considering global tailwinds and our strengths as a country. Globally, there is a realignment of value chains as well as a need to rebuild critical infrastructure for the digital age. Most physical industries are ripe for transformation.
In India’s dynamic startup landscape, biotech is where matter of purpose trumps all discourse of profitability
In India’s dynamic startup landscape, although there is much talk about profitability, there has also been a growing shift towards creating purpose-driven startups. Biotech is one such sector, where the matter of purpose trumps all discourse of profitability.
